Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-754807 + trastuzumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
BMS-754807 + trastuzumab is an investigational combination therapy composed of BMS-754807, a small molecule, orally available, reversible dual inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) family kinases, and trastuzumab (marketed as Herceptin), a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/ERBB2). BMS-754807 blocks IGF-1R and IR kinase signaling, interfering with growth and survival pathways in cancer cells, while trastuzumab binds to HER2 and inhibits its signaling, inducing cellular cytotoxicity. This combination is being evaluated primarily for advanced or metastatic HER2-positive breast cancer, especially in cases resistant to trastuzumab monotherapy, with the goal of overcoming resistance through dual pathway inhibition[1][3][5].
- Other names
- BMS-754807 + HerceptinBMS-754807 plus trastuzumabBMS754807 plus trastuzumabBMS 754807 plus trastuzumab
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on BMS-754807 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-754807 + trastuzumab.